Interstitial pneumonitis and lung fibrosis during adjuvant treatment of melanoma with interferon alpha according to the Kirkwood schedule.
Puente Vázquez
J
J
Moreno Antón
F
F
Grande Pulido
E
E
López Tarruella-Cobo
S
S
Pérez Segura
P
P
Díaz-Rubio
E
E
D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects*; D003924:Diabetes Mellitus, Type 2; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D017563:Lung Diseases, Interstitial / Q000139:chemically induced / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000473:pathology; D008545:Melanoma / Q000188:drug therapy*; D010300:Parkinson Disease; D011658:Pulmonary Fibrosis / Q000139:chemically induced / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000473:pathology; D011994:Recombinant Proteins; D012878:Skin Neoplasms / Q000188:drug therapy*; D014057:Tomography, X-Ray Computed; D014397:Tuberculosis, Pulmonary
D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins